Join to View Full Profile
1021 Morehead Medical DrSte ACharlotte, NC 28204
Phone+1 980-442-2000
Fax+1 980-442-5241
Dr. Voorhees is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2001 - 2004
- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1997 - 2001
- University of Michigan Medical SchoolClass of 1997
Certifications & Licensure
- NC State Medical License 2001 - 2025
- WI State Medical License 1998 - 2001
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Top MD Consumers Checkbook
Clinical Trials
- Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy Start of enrollment: 2008 Aug 01
- Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2008 Oct 01
- Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
- Join now to see all
Publications & Presentations
PubMed
- Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer
Blood Advances. 2025-03-15 - BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement.Mahmoud R Gaballa, Omar Castaneda Puglianini, Adam Cohen, Dan Vogl, Alfred Chung
Blood Advances. 2025-03-11 - 2 citationsInternational myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.Luciano J Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal
Leukemia. 2025-03-01
Journal Articles
- International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman DiseaseAaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood
Abstracts/Posters
- Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Result...Peter M. Voorhees, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Ex Vivo Assessment of Tnb-383B, a Bcma-Bispecific Antibody, Against Primary Tumor and Endogenous T Cells from Relapsing Multiple Myeloma Patients2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab ﴾Dara﴿, Bortezomib ﴾V﴿, Lenalidomide ﴾R﴿, and De...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- International Myeloma Foundation Medical Student Scholars for Health Equity in Myeloma Present Posters at the 2024 NMA Annual Convention & Scientific AssemblyAugust 15th, 2024
- ATLAS Trial: Risk-Adapted Triplet Maintenance Therapy May Benefit Some Patients with Multiple MyelomaAugust 1st, 2022
- Frontline Therapy for Multiple MyelomaMay 3rd, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: